Current COVID-19 Vaccine Update

ABHM Covid-19 Vaccine Information Video

(Click image above to view video)

ABHM is very excited about the COVID-19 vaccine coming to our communities.

Each community will receive the COVID-19 vaccine as soon as each state sets up their own vaccination process.

Although ABHM is not requiring staff to get vaccinated, we strongly encourage all employees to get the vaccination. Not only to safeguard your own health but to ensure the health and safety of everyone.

We realize some individuals may be apprehensive about getting the vaccination and have questions on how the vaccine works as well as side effects. Here is a link to a video message from Dr. Sing Palat, MD addressing some of the concerns regarding the vaccine.

Sing Palat, MD, is an internist and geriatrician of 14 years and is a certified medical director.  As an associate of LTC Rehab Consultants, she provides care in nursing facilities and currently collaborates with Mountain Vista medical director Dr. Reza Esfahani on the COVID-19 response.   Dr. Palat is on the Board of CMDA The Colorado Society of Post-acute and Long-term Care.

If you have any further questions, do not hesitate to email us at



Update 3-3-21

We have had a great response from our residents and team members to the vaccine clinics held at our community. At this point we are pleased to say that all residents and staff who chose to be vaccinated have received both doses.

We want to share the vaccination results thus far:

Residents Vaccination Rates:
• 95.6% Assisted Living
• 90.9% Skilled Nursing Facility
• 79.3% Independent Living

Team Members Vaccination Rates:
• 69.03% All Departments

Vaccination for New Residents and Staff

Elm Crest has partnered with the local public health department to provide new residents and new staff members with the opportunity to receive the vaccination on an as needed basis.

Visitation Policies

While the percentage of people vaccinated is high we are required to continue limiting visitation, resident interaction and community activities. Thank you for your understanding.

ABHM has set up a designated email address to best respond to any questions, comments, or concerns specifically related to the COVID-19 vaccine.



COVID-19 Vaccine Frequently Asked Questions

Is the vaccine safe?

The Advisory Committee on Immunization Practices (ACIP) and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC)] review vaccine safety data. For COVID-19, ACIP has formed a separate Vaccine Safety Technical (VaST) to provide timely evaluation of vaccine safety, both pre- and post-licensure.

The Centers for Disease Control (CDC) is adding further monitoring programs to health care workers to analyze results six weeks after vaccination. Long-term Care is required to report all vaccinations through the National Healthcare Safety Network (NHSN). Most adverse side effects occur within six weeks of vaccine administration, and the FDA has required eight weeks of safety monitoring so it can track any side effects. FDA advises a minimum of 3,000 participants to assess safety. The current phase 3 trials have 30,000 to 50,000 participants. This really demonstrates how safety is a top priority for the FDA and the medical community.

Is ABHM requiring employees and their residents to take the vaccine?

Staff and residents are not required to take the vaccine.

Will personal protective equipment (PPE) guidelines be relaxed if the staff, residents and members are vaccinated?

Until ABHM knows the effectiveness of the vaccine, PPE guidelines will not be relaxed.

Is the vaccine one dose or a series?

The two initial vaccines projected for release are two-dose series vaccines and are not interchangeable. It’s important you schedule your second dose while getting your first dose because your booster must be from the same manufacturer.

Why can’t I have the vaccine now when others are receiving it?

At this time, there is not enough vaccine for everyone requesting it. Our state health departments are working with Walgreens or CVS to distribute the vaccine to those most at risk, including those living in long-term care facilities. The best way to prevent COVID-19 is by wearing a mask, practicing social distancing and washing your hands frequently.

If I already contracted COVID-19, do I need a vaccination?

ABHM is recommending all residents and employees get the COVID-19 vaccine, regardless of whether they have recovered from a previous COVID-19 infection. According to the CDC, there is not enough information currently available to say if or for how long after infection someone is protected from getting COVID-19 again. This is called natural immunity. Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed for a better understanding.

Does insurance cover the vaccine?

Private health insurance companies, as well as government insurance programs like Medicare, will cover the vaccination cost. You will need to have your insurance information when getting your vaccine.



COVID-19 Vaccine: Is It for You?

Travis LaCore, PharmD, BCGP, NREMT, FF2. ABHM Subject Matter Expert of Pharmacy

A COVID-19 vaccine has the potential to bring the pandemic to an end at a greater speed than any other intervention available. Vaccination will provide protection to an individual and reduce the chances of spreading as more people get the vaccine.

Despite the potential benefit of the COVID-19 vaccine to drastically reducing the spread of infection, there remains a high level of apprehension among the public regarding the safety of the vaccine. Although the development of a COVID-19 vaccine has been rapid, the research and development on a coronavirus vaccine is not new, nor are the methods used to produce the vaccine. The vaccine approval process also remains fundamentally unchanged and must include strong evidence of vaccine safety and effectiveness. Research and development of coronavirus vaccines date as far back to 2002 and 2012, SARS (Severe Acute Respiratory Syndrome) outbreak of 2002, and MERS (Middle Eastern Respiratory Syndrome) outbreak of 2012. Researchers’ directed the development of the COVID-19 vaccine utilizing the prior research on these outbreaks. One type of vaccine being developed, the mRNA vaccine, is a type of vaccine that has not been used in the US vaccine market previously, however it has been researched for decades in other areas such as cancer treatments.

The Pfizer BioNTech COVID-19 vaccine is a 2-dose series, with an estimated effectiveness rate of 95% at 28 days after the initial dose. The most common adverse reactions reported were injection site reaction, fatigue, headache, muscle pain, chills, joint pain, and fever, which are common reactions with any vaccine.

The next COVID-19 vaccine to be considered for an FDA EUA is the Moderna COVID-19 vaccine, which is scheduled to be reviewed by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) on December 17, 2020.

For questions and concerns about the vaccines, please contact your health care provider.